Deciphering the molecular pathways of saroglitazar: A dual PPAR α/γ agonist for managing metabolic NAFLD DOI
Devaraj Ezhilarasan

Metabolism, Journal Year: 2024, Volume and Issue: 155, P. 155912 - 155912

Published: April 11, 2024

Language: Английский

The role of peroxisome proliferator-activated receptors (PPAR) in immune responses DOI
Anthos Christofides,

Eirini Konstantinidou,

Chinmay Jani

et al.

Metabolism, Journal Year: 2020, Volume and Issue: 114, P. 154338 - 154338

Published: Aug. 11, 2020

Language: Английский

Citations

455

Emerging therapeutic approaches for the treatment of NAFLD and type 2 diabetes mellitus DOI
Daniel Ferguson, Brian N. Finck

Nature Reviews Endocrinology, Journal Year: 2021, Volume and Issue: 17(8), P. 484 - 495

Published: June 15, 2021

Language: Английский

Citations

342

Targeting fibrosis: mechanisms and clinical trials DOI Creative Commons

Manyu Zhao,

Liqun Wang, Mengzhu Wang

et al.

Signal Transduction and Targeted Therapy, Journal Year: 2022, Volume and Issue: 7(1)

Published: June 30, 2022

Fibrosis is characterized by the excessive extracellular matrix deposition due to dysregulated wound and connective tissue repair response. Multiple organs can develop fibrosis, including liver, kidney, heart, lung. such as liver cirrhosis, idiopathic pulmonary cystic fibrosis caused substantial disease burden. Persistent abnormal activation of myofibroblasts mediated various signals, transforming growth factor, platelet-derived fibroblast growh has been recongized a major event in occurrence progression fibrosis. Although mechanisms driving organ-specific have not fully elucidated, drugs targeting these identified aberrant signals achieved potent anti-fibrotic efficacy clinical trials. In this review, we briefly introduce aetiology epidemiology several diseases, kidney cardiac Then, summarise cells (epithelial cells, endothelial immune fibroblasts) their interactions addition, also focus on signaling pathways therapeutic targets that regulate myofibroblast activation, cross-linking, metabolism, inflammation Finally, discuss based This review provides reference for further research mechanism, drug development,

Language: Английский

Citations

258

Legacy and Emerging Per- and Polyfluoroalkyl Substances: Analytical Techniques, Environmental Fate, and Health Effects DOI Open Access
Richard A. Brase, Elizabeth J. Mullin, David C. Spink

et al.

International Journal of Molecular Sciences, Journal Year: 2021, Volume and Issue: 22(3), P. 995 - 995

Published: Jan. 20, 2021

Due to their unique chemical properties, per- and polyfluoroalkyl substances (PFAS) have been used extensively as industrial surfactants processing aids. While several types of PFAS voluntarily phased out by manufacturers, these chemicals continue be ecological public health concern due persistence in the environment presence living organisms. Moreover, while compounds referred “legacy” remain environment, alternative emerged replacements for legacy predecessors are now detected numerous matrices. In this review, we discuss historical uses PFAS, recent advances analytical techniques analysis compounds, fate environment. addition, evaluate current biomonitoring studies human exposure emerging examine associations with impacts, including cancer- non-cancer-related outcomes. Special focus is given short-chain perfluoroalkyl acids (PFAAs) ether-substituted, alternatives hexafluoropropylene oxide dimer acid (HFPO-DA; tradename GenX), 4,8-dioxa-3H-perfluorononanoic (DONA), 6:2 chlorinated polyfluoroethersulfonic (6:2 Cl-PFESA; F-53B).

Language: Английский

Citations

213

PPARγ/PGC1α signaling as a potential therapeutic target for mitochondrial biogenesis in neurodegenerative disorders DOI
Sumit Jamwal, Jennifer K. Blackburn, John D. Elsworth

et al.

Pharmacology & Therapeutics, Journal Year: 2020, Volume and Issue: 219, P. 107705 - 107705

Published: Oct. 9, 2020

Language: Английский

Citations

145

Tetramethylpyrazine: A review on its mechanisms and functions DOI Creative Commons
Jianguo Lin, Qingqing Wang,

Simin Zhou

et al.

Biomedicine & Pharmacotherapy, Journal Year: 2022, Volume and Issue: 150, P. 113005 - 113005

Published: April 25, 2022

Ligusticum chuanxiong Hort (known as Chuanxiong in China, CX) is one of the most widely used and long-standing medicinal herbs China. Tetramethylpyrazine (TMP) an alkaloid active components CX. Over past few decades, TMP has been proven to possess several pharmacological properties. It treat a variety diseases with excellent therapeutic effects. Here, characteristics molecular mechanism recent years are reviewed, emphasis on signal-regulation TMP. This review shows that many physiological functions, including anti-oxidant, anti-inflammatory, anti-apoptosis properties; autophagy regulation; vasodilation; angiogenesis mitochondrial damage suppression; endothelial protection; reduction proliferation migration vascular smooth muscle cells; neuroprotection. At present, treating cardiovascular, nervous, digestive system conditions, cancer, other conditions achieved good curative The involves multiple targets, pathways, bidirectional regulation. is, thus, promising drug great research potential.

Language: Английский

Citations

128

PPAR-α Modulators as Current and Potential Cancer Treatments DOI Creative Commons
Yan Tan, Mina Wang, Yang Ke

et al.

Frontiers in Oncology, Journal Year: 2021, Volume and Issue: 11

Published: March 23, 2021

Cancer is one of the leading causes mortality worldwide. PPAR modulators may hold great potential for management cancer patients. Indeed, PPARs are critical sensors and regulators lipid, they able to promote eNOS activation, regulate immunity inflammation response, affect proliferation differentiation cells. Cancer, a name given group diseases, characterized by multiple distinctive biological behaviors, including angiogenesis, abnormal cell proliferation, aerobic glycolysis, inflammation, etc. In last decade, emerging evidence has shown that PPAR-α, nuclear hormone receptor, can modulate carcinogenesis via exerting effects on or several characteristic pathological behaviors cancer. Therefore, multi-functional have substantial promise in various types therapies. This review aims consolidate functions as well discuss current applications PPAR-α agonists antagonists tackling

Language: Английский

Citations

112

Therapeutic targets, novel drugs, and delivery systems for diabetes associated NAFLD and liver fibrosis DOI
Virender Kumar, Xiaofei Xin, Jingyi Ma

et al.

Advanced Drug Delivery Reviews, Journal Year: 2021, Volume and Issue: 176, P. 113888 - 113888

Published: July 24, 2021

Language: Английский

Citations

109

The lipid flippase SLC47A1 blocks metabolic vulnerability to ferroptosis DOI Creative Commons
Zhi Lin,

Jiao Liu,

Fei Long

et al.

Nature Communications, Journal Year: 2022, Volume and Issue: 13(1)

Published: Dec. 27, 2022

Abstract Ferroptosis is a type of regulated necrosis caused by unrestricted lipid peroxidation and subsequent plasma membrane rupture. However, the remodeling mechanism that determines sensitivity to ferroptosis remains poorly understood. Here, we report previously unrecognized role for flippase solute carrier family 47 member 1 (SLC47A1) as regulator survival during ferroptosis. Among 49 phospholipid scramblases, flippases, floppases analyzed, only SLC47A1 had mRNA was selectively upregulated in multiple cancer cells exposed ferroptotic inducers. Large-scale lipidomics functional analyses revealed silencing increased RSL3- or erastin-induced favoring ACSL4-SOAT1–mediated production polyunsaturated fatty acid cholesterol esters. We identified peroxisome proliferator activated receptor alpha (PPARA) transcription factor transactivates SLC47A1. The depletion PPARA similarly sensitized induction, whereas transfection-enforced re-expression restored resistance PPARA-deficient cells. Pharmacological genetic blockade PPARA-SLC47A1 pathway anticancer activity inducer mice. These findings establish direct molecular link between transporters, which may provide metabolic targets overcoming drug resistance.

Language: Английский

Citations

101

The Many Facets of PPAR-γ Agonism in Obesity and Associated Comorbidities: Benefits, Risks, Challenges, and Future Directions DOI
Dimitris Kounatidis, Natalia G. Vallianou, Eleni Rebelos

et al.

Current Obesity Reports, Journal Year: 2025, Volume and Issue: 14(1)

Published: Feb. 12, 2025

Language: Английский

Citations

2